Correlation of tumor markers p53, bcl-2, CD34, CD44H, CD44v6, and Ki-67 with survival and metastasis in laryngeal squamous cell carcinoma

Archives of Otolaryngology - Head and Neck Surgery

Volumn 122, Issue 6, 1996, Pages 627-632

  Spafford, Michael F ^a   Koeppe, John ^a   Pan, Zhaoxing ^a   Archer, Philip G ^a   Meyers, Arlen D ^a,b   Franklin, Wilbur A ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; GENE PRODUCT; HERMES ANTIGEN; PROTEIN P53; TUMOR MARKER;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CELL ADHESION; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARYNX CARCINOMA; MAJOR CLINICAL STUDY; METASTASIS; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

EID: 0029992488     PISSN: 08864470     EISSN: None     Source Type: Journal    
DOI: 10.1001/archotol.1996.01890180035010     Document Type: Article

References (26)

1. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994;54:4855-4878.
2. Shimaya K, Shiozaki H, Inoue M, et al. Significance of p53 expression as a prognostic factor in oesophageal squamous cell carcinoma. Virchows Arch. 1993;442:271-276.
3. Sauter ER, Ridge JA, Gordon J, et al. p53 correlates with increased survival in patients with squamous cell carcinoma of the tongue base. Am J Surg. 1992; 164:651-653.
4. Brachman DG, Beckett M, Graves D, et al. p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines. Cancer Res. 1993; 53:3667-3669.
5. Gesprini G, Weidner N, Maluta S, et al. Intratumoral microvessel density and p53 protein, correlation with metastasis in the head-and-neck squamous cell carcinoma. Int J Cancer. 1993;55:735-744.
6. Miyashita T, Krajewski S, Krajewski M, et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene. 1994; 9:1799-1805.
7. +/DR - phenotypes with shorter survival. Leukemia. 1992;6:393-399.
8. Kirchmann TT, Prieto VG, Smoller BR. CD34 staining pattern distinguishes basal cell carcinoma from trichoepithelioma. Arch Dermatol. 1994;130:589-592.
9. Traweek ST, Kandalaft PL, Mehta P, et al. The human hematopoeitic progenitor cell antigen (CD34) in vascular neoplasia. Am J Clin Pathol. 1991;96:25-31.
10. Jackson DG, Schenker T, Waibel R, Bell JJ, Stahel RA. Expression of alternatively spliced forms of the CD44 extracellular-matrix receptor on human lung carcinomas. Int J Cancer. 1994;8:110-115.
11. Bartolazzi A, Peach R, Aruffo A, Stamenkovic I. Interaction between CD44 and hyaluronate is directly implicated in the regulation of tumor development. J Exp Med. 1994;180:53-66.
12. Fox SB, Fawcett J, Jackson DG, et al. Normal human tissues, in addition to some tumors, express multiple different CD44 isoforms. Cancer Res. 1994; 54:4539-4546.
13. Penno MB, August JT, Baylin SB, et al. Expression of CD44 in human lung tumors. Cancer Res. 1994;54:1381-1387.
14. Gottardi O, Tabiandon D, Scanzi F, et al. Clinical and prognostic usefulness of Ki67 determination in breast carcinoma. Pathologica. 1992;84:15-22.
15. Scagliotti GV, Micela M, Gubetta L, et al. Prognostic significance of Ki67 labelling in resected non small cell lung cancer. Eur J Cancer. 1993;29A:363-365.
16. Roland NJ, Caslin AW, Bowie GL, Jones AS. Has the cellular proliferation marker Ki67 any clinical relevance in squamous cell carcinoma of the head and neck? Clin Otolaryngol. 1994;19:13-18.
17. Cox DR, Oakes D. Analysis of Survival Data. London, England: Chapman & Hall Ltd; 1984:91-111.
18. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip-1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 1993;75:805-816.
19. El-Deiry W, Tokino T, Velculescu VE, et al. WAF-1, a potential mediator of p53 tumor suppression. Cell. 1993;75:817-825.
20. Smith ML, Chen IT, Fornace AJ. Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. Nature. 1994;266:1376-1379.
21. Clarke AR, Purdie CA, Harrison DJ, et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature. 1993;362:849-852.
22. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell. 1992;70:523-526.
23. Field JK, Pavelic ZP, Spandidos DA, Stambrook PJ, Jones AS, Gluckman JL. The role of the p53 tumor suppressor gene in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 1993;119:1118-1122.
24. Stewart BW. Mechanisms of apoptosis: integration of genetic, biochemical and cellular indicators. J Natl Cancer Inst. 1994;86:1286-1295.
25. Shin DM, Kim J, Ro JY, et al. Activation of p53 gene expression in premalignant lesions during head and neck tumorigenesis. Cancer Res. 1994;54:321-326.
26. Pavelic ZP, Li Y, Stambrook PJ, et al. Overexpression of p53 protein is common in premalignant head and neck lesions. Anticancer Res. 1994;14:2259-2266.